---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-300535"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2022-12-08T23:59:59+00:00"
generated_at: "2026-06-21T07:15:52.558973+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corcept settles patent litigation with Hikma; generic Korlym entry set for October 2034

## Summary
- Settlement with Hikma resolves patent litigation over generic Korlym in District of New Jersey.
- Hikma granted right to sell generic Korlym in U.S. beginning October 1, 2034 or earlier under customary conditions.
- Similar patent litigation against Teva Pharmaceuticals USA remains pending.
- Settlement subject to court consent judgment and FTC/DOJ review.
- CEO Belanoff noted the settlement allows focus on growing Korlym and developing cortisol modulator pipeline.

## SEC filing metadata
- accession: 0001193125-22-300535
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2022-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000119312522300535/0001193125-22-300535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000119312522300535/d430330d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-300535
- JSON: https://secwatch.observer/filing/0001193125-22-300535.json
- Plain text: https://secwatch.observer/filing/0001193125-22-300535.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.